Penn Medicine Provider
Hospital Medicine
Emma Lundsmith, MD
Accepting new patients
Sees patients age 18 and up
Penn Hospital Medicine Pennsylvania Hospital

About me

  • Clinical Assistant Professor of Medicine (Medicine Affiliates)

Education and training

  • Medical School: Jefferson Medical College
  • Residency: Thomas Jefferson University Hospital

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Princeton Medical Center: Has privileges to treat patients in the hospital.
Dr. Lundsmith is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Chatterji P, Williams PA, Whelan KA, Samper FC, Andres SF, Simon LA, Parham LR, Mizuno R, Lundsmith ET, Lee DS, Liang S, Wijerante HS, Marti S, Chau L, Giroux V, Wilkins BJ, Wu GD, Shah P, Tartarglia GG, Hamilton KE Posttranscriptional regulation of colonic epithelial repair by RNA binding protein IMP1/IGF2BP1. , EMBO Rep, 20(6): 2019,e47074


Li JC, Lundsmith E No Stones, Some Groans, and Psychiatric Overtones with "Non-specific" Splenomegaly. , Cureus, 11(5): 2019,e4638


Long AG, Lundsmith ET, Hamilton KE Inflammation and Colorectal Cancer , Current Colorectal Cancer Reports, 13(4): 2017


Lundsmith E, Zheng M, McCue P, Niu B Chronic Gastric Ischemia Leading to Gastric Perforation. , ACG Case Rep J, 3(4): 2016,e194


Hamilton KE, Chatterji P, Lundsmith ET, Andres SF, Giroux V, Hicks PD, Noubissi FK, Spiegelman VS, Rustgi AK Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon. , Mol Cancer Res, 13(11): 2015,1478-86


Hamilton KE, Noubissi FK, Katti PA, Hahn CM, Davey SR, Lundsmith ET, Klein-Szanto AJ, Rhim AD, Spiegelman VS, Rustgi AK IMP1 promotes tumor growth, dissemination and a tumor-initiating cell phenotype in colorectal cancer cell xenografts. , Carcinogenesis, 34(11): 2013,2647-54


Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. , Oncogene, 30(28): 2011,3153-62


Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies T, Weinstein L, Chen M, Rosen N, Ghossein R, Knauf J, Fagin J Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. , PNAS, 108(4): 2011,1615-20


Iocca HA, Plant SR, Wang Y, Runkel L, O’Connor BP, Lundsmith E, Hahm K, van Deventer HW, Burkly LC, Ting JPY TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. , J Neuroimmunol, 194((1-2)): 2008,97-106